Ascend Advanced Therapies, which has been on an expansion tear since debuting three years ago, inked a deal with EW ...
1d
Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies ...
Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology ...
Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...
The multicenter Phase1b open-label dose escalation study (NCT05973630) will evaluate safety, pharmacodynamics, efficacy, and immunogenicity in children receiving intravenous ATA-200, a single-dose ...
Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...
This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...
Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent ...
Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.
Ascend’s fill/finish capacity in the US will also be expanded. “We founded Ascend with a vision to quilt together the best operators and technologies within the advanced manufacturing field. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback